FindTrial
Sign In

Comparing and evaluating the effect of 0.05% Zoledronate as medicated gel in gums for the treatment of patients with pyorrhoea alone and patients with pyorrhoea and diabetes.

Comparative evaluation of 0.05% Zoledronate gel as Local drug delivery system in chronic Periodontitis and patients of chronic Periodontitis with type 2 Diabetes Mellitus - A randomised clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025188
Enrollment
60
Registered
2020-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: 0.05% Zoledronate gel as Local drug delivery system: 0.05% Zoledronate gel as Local drug delivery system in patients with Chronic periodontitis and patients with chronic periodontitis a

Sponsors

SCB Dental College and Hospital Cuttack
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Systemically healthy patient (except for well controlled Type 2 DM). 2. Pocket depths >= 5mm measured with UNC 15 probe. 3. Clinical attachment loss >= 4mm measured with UNC 15 probe. 4. Vertical bone loss >= 3mm seen on intraoral periapical radiograph. 5. Patients with well controlled Type 2 Diabetes Mellitus classified based on criteria of American Diabetic Association (ADA) and glycated haemoglobin levels (HbA1C). 6. No history of periodontal therapy in the preceding 6 months. 7. No use of antibiotics in the preceding 6 months. 8. Non smokers

Exclusion criteria

Exclusion criteria: 1. With known systemic disease (other than type 2 diabetes) 2. With known or suspected allergy to ZLN/ bisphosphonate group. 3. Those on systemic ZLN/Bisphosphonate therapy 4. Individuals with Aggressive periodontitis 5. Use of tobacco in any form and alcohol 6. Immunocompromised individuals 7. Pregnant or lactating females 8. Tooth with hopeless prognosis. 9. Serum creatinine clearance Ë? 35ml/min or in patients with evidence of acute renal impairment.

Design outcomes

Primary

MeasureTime frame
Change in radiographic defect depth reduction percentage from baseline.Timepoint: 3 months and 6 months.—

Secondary

MeasureTime frame
Change in Probing depths, Clinical attachment levels, Modified sulcular bleeding index, and Plaque index from baseline.Timepoint: 3 months and 6 months—

Countries

India

Contacts

Public ContactAsit Kumar Mishra

SCB Dental College and Hospital, Cuttack

drsubash007@gmail.com9437008298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026